Topic review

MicroRNA Biomarkers in IBD

Subjects: Pathology & Pathobiology View times: 34
Submitted by: Jaslin James

Definition

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). These are chronic autoimmune diseases of unknown etiology affecting the gastrointestinal tract. The IBD population includes a heterogeneous group of patients with varying disease courses requiring personalized treatment protocols. The complexity of the disease often delays the diagnosis and the initiation of appropriate treatments. In a subset of patients, IBD leads to colitis-associated cancer (CAC). MicroRNAs are single-stranded regulatory noncoding RNAs of 18 to 22 nucleotides with putative roles in the pathogenesis of IBD and colorectal cancer. They have been explored as biomarkers and therapeutic targets. Both tissue-derived and circulating microRNAs have emerged as promising biomarkers in the differential diagnosis and in the prognosis of disease severity of IBD as well as predictive biomarkers in drug resistance. In addition, knowledge of the cellular localization of differentially expressed microRNAs is a prerequisite for deciphering the biological role of these important epigenetic regulators and the cellular localization may even contribute to an alternative repertoire of biomarkers.

1. Introduction

Inflammatory bowel disease (IBD) refers to Crohn’s disease (CD) and ulcerative colitis (UC). In UC, inflammation generally includes the rectum and extends towards the coecum and remains confined to the colon. In contrast, in CD, inflammation can involve any part of the gastrointestinal tract (GI) from the oral cavity to the anus. Both CD and UC are associated with multiple pathogenic factors such as environmental changes, the array of susceptibility gene variants, qualitatively and quantitatively abnormal gut microbiota and broadly dysregulated immune response [1]. Although CD and UC have some common pathological and clinical characteristics, they have several different attributes that imply that they are two distinct disease subtypes. In CD, fissuring ulceration and sub-mucosal fibrosis can be observed along with granulomatous inflammation. In UC, the inflammatory process always involves the rectum [2] and general histological findings include crypt distortion, infiltration of lymphocytes and granulocytes and chronic inflammation, usually confined to the lamina propria [3]. The diagnosis of IBD is usually established by a collective assessment of clinical presentation and endoscopic, histopathological, radiographic and laboratory findings. A definitive diagnosis of IBD cannot be made without detailed endoscopic and histologic assessment [4]. However, a subset of IBD cases cannot be classified as either CD or UC but are categorized as IBD unclassified (IBDU). Molecular biomarkers may support differential diagnosis of IBDU cases into CD or UC, or even be helpful in determining if IBDU represents a unique IBD diagnostic entity.

IBD starts developing at a younger age, including in infants [5], and is often characterized by a considerable diagnostic and therapeutic challenge because of the disease’s clinical features and associated complications. The prevalence of IBD in the Western world is projected to be up to 0.5% of the overall population [6]. In Denmark, where one of the highest annual incidence rates of IBD in Europe is seen, the incidence has been increasing over the last three decades [7]. In 2013, the incidence was 9.1 per 100,000 persons and 18.6 per 100,000 persons for CD and UC, respectively [8]. Since the turn of the 21st century, IBD has become a global disease with accelerating incidence rates also in developing countries whose societies have adopted a western diet and lifestyle. Although the incidence rate has become steady in western countries, the burden remains high, as prevalence exceeds 0.3%. The chronical inflammatory condition in the affected colon of IBD patients has been linked to development of neoplastic lesions in the colon. Several studies have shown a higher incidence of colorectal cancer (CRC) in IBD patients [9][10][11]. No biomarkers exist for the identification of IBD patients at risk of developing colitis-associated cancer (CAC), strongly advocating for more translational research in this field.

In this review, we give an overview of microRNAs (miRNAs) as candidate biomarkers in the IBD diagnostic assessment. Changes in miRNA levels are associated with disease development and can be measured both within the diseased tissue and in the circulation by a variety of molecular methods. MiRNAs have been found to be well conserved in archived tissue specimens, enabling retrospective analyses of clinical sample cohorts.

2. MicroRNA—An Introduction

MiRNAs play a central role in the regulation of several immune-mediated disorders including IBD [12][13][14]. MiRNAs are a group of small noncoding RNAs, approximately 18–22 nucleotides [15] which are found conserved across species. Their discovery was first described first in 1993 in Caenorhabditis elegans [16]. MiRNAs are transcribed as primary transcripts by RNA polymerase, processed into a precursor miRNA by the RNase III enzyme, Drosha, and exported from the nucleus to the cytoplasm. The precursor miRNA is cleaved by the RNase III enzyme, Dicer, into its mature form, which becomes stably incorporated into an RNA induced silencing complex (RISC). The miRNA guides the binding of the RNA-induced silencing complex to complementary sequences in the 3′-untranslated regions (UTR) of target mRNA molecules, resulting in either mRNA degradation or translational inhibition [17]. During stages of miRNA biogenesis, several factors can influence the development of the mature miRNA. These include regulation of transcription, cleavage of the stem loop structures by Drosha and Dicer enzymes, and editing as well as regulation of miRNA turnover. Each of these mechanisms acts as part of a signaling network that modulates gene expression in response to cellular or environmental changes.

MiRNA expression has been shown to be of importance in a wide variety of human diseases such as cancer, autoimmune, cardiovascular, and neurodegenerative diseases [18][19][20][21][22][23][24]. The miRNAs not only circulate in the human peripheral blood in a stable form, they are also present in other body fluids such as urine, saliva, milk, cerebrospinal fluid, and feces [25][26][27][28]. The miRNAs are engaged in disease origin and development, and some are pathology-specific [29], thus, changes in miRNA expression profiles have been addressed for applications in early detection as well as prognostics, diagnostic classification and drug response prediction.

3. MiRNAs in IBD

In IBD, miRNAs have been found to be involved in pathogenesis and have been identified as both  diagnostic biomarkers and therapeutic targets [30]. Most of the recent research in the IBD field has measured levels of circulating miRNAs in body fluids such as blood or feces, and in homogenized tissue biopsies using techniques like microarray profiling, RT-qPCR, and NGS [31][32][33][34]. Studies have also performed tissue miRNA expression analysis using in situ hybridization (ISH) methods [35][36][37]. ISH methods for expression analyses of miRNAs can determine the cellular origin of miRNA expression and can offer insight into the biology of the disease mechanisms involved. Local expression levels of miRNAs can greatly vary from those of circulating miRNAs, e.g., due to contribution of miRNAs from circulating cells. Esquela-Kerscher and Slack [38] proposed that tumor cells release miRNAs into the neighboring microenvironment and enter circulation during angiogenesis. Some studies suggest that this likely occurs through exosomal release from cells [39][40]. Changes in the levels of circulating miRNA may occur due to other inflammatory reactions or the host immune response rather than only due to the intrinsic changes within the lesion [41]. Thus, as discussed further below, it is not surprising that miRNAs analyzed in tissue biopsies poorly correlate with those found in the circulation [42]

There is an increasing interest in exploring epigenetic mechanisms in common diseases, with notable progress in characterizing the contribution of miRNAs [43]. In their 2008 study, Wu et al. found that miRNAs regulate colonic epithelial cell-derived chemokine expression and were the first to relate miRNAs to IBD [44]. The field of miRNA research has grown rapidly after their discovery in human disease biology including in IBD [43]. We have listed a series of IBD-related miRNA studies from recent years in Table 1, with a focus on sample type and quantitative method. MiR-21, miR-155, and miR-31 have repeatedly been identified and seem to be the most studied miRNAs related to IBD [45][46][47][48]. MiR-21 is possibly the most intriguing miRNA involved in IBD, with associations between miR-21 and IBD being replicated in several studies, as well as functional relevance reported in mouse models of IBD [49][50]. Each miRNA can potentially target hundreds of mRNAs resulting in mRNA destabilization and/or inhibition of translation, however, restricted to a specific cellular context, the number of relevant targetable transcripts is probably quite low.

MiRNAs regulate important cellular functions such as cell differentiation and proliferation and signal transduction and apoptosis and exhibit highly specific regulated patterns of gene expression [15]. In autoimmune diseases, miRNAs can act through interference with inflammatory signaling pathways, such as the nuclear transcription factor kappa B (NF-κB) pathway, IL23/IL23R pathway, and IL-6/STAT3 pathway[51][52][53][54][55]. Studying the RhoB pathway of cell adhesion in UC mucosa and cultured colon cancer cells, Yang et al. [36] examined the role of miR-21 in regulation of intestinal epithelial barrier function and found that miR-21 induced the degradation of RhoB mRNA, reduction in RhoB protein, causing loss of tight junctions in intestinal epithelial cells. Tian et al. showed miR-31 to be highly expressed in tissues from IBD patients, and miR-31 reduced the inflammatory response in the Dextran Sodium Sulphate (DSS)-induced colitis mouse model (see below), by preventing the expression of inflammatory cytokine receptors such as IL7R and IL17RA and signaling proteins such as GP130 [56]. Another study based on the DSS model showed that miR-155 directly binds to SHIP-1 mRNA and causes a significant decrease in SHIP-1 levels, which regulate cell membrane trafficking, and thereby contribute to the pathogenesis of colitis [57]. Taken together, these examples indicate the complexity of how miRNAs may act through signaling pathways in the biological settings of IBD.

Studies of circulating miRNAs have shown that miRNAs are potential candidates as biomarkers for diagnosing IBD and various other diseases [58][59][60][61][62]. The high stability of miRNAs in the body fluids and the ability to obtain rapid and accurate quantitative estimates are some merits of using circulating miRNAs as biomarkers in IBD [28]. MiRNAs are not only interesting tools for diagnosis, but also for potential future therapeutic applications by miRNA mimics or miRNA antagonists [63][64].

Table 1. A summary of studies on microRNA research in inflammatory bowel disease (IBD). CD: Crohn’s disease, UC: Ulcerative colitis, HC: Healthy controls, RT-qPCR: Quantitative real time polymerase chain reaction, Biopsy: colon tissue biopsy, ISH: In situ hybridization, QISH: Quantitative in-situ hybridization, PBMC: Peripheral blood mononuclear cells, DSS: Dextran sodium sulphate, AOM: Azoxymethane, TNF: Tumor necrosis factor alpha.

#

MiRNAs

Disease Subtype

Sample Type

Techniques Used

Outcome

Reference

1

miR-16, miR-29a, miR-199a-5p, miR-363-3p, miR-340, miR-532-3p, miRplus-1271, miR-140-3p, miR-127-3p, miR-196b, miR-877, miR-150

CD, UD, HC

Serum, Biopsy

RT-qPCR, Microarray

Mixed outcomes

[42]

2

miR-223-3p, miR-31-5p

CD, HC

Biopsy

Nano string

Mir-223-3p expression showed age and sex effects and miR-31-5p expression was driven by location

[45]

3

miR-29b

CD

Fibroblasts

RT-qPCR

MCL-1 is modulated in CD fibrosis by miR-29b via IL-6 and IL-8

[65]

4

miR-141, miR-200a, miR-200b, miR-200c

UC, CD

Biopsy

RT-qPCR

All investigated miRNAs were significantly down regulated in CD, and 3 of them were downregulated in UC in comparison to the normal or the least affected mucosa.

[66]

5

miR-141

UC, HC

Biopsy

Microarray, RT-qPCR

MiR-141 plays a role in the bowel inflammation of individuals with active UC via down regulation of CXCL5 expression.

[67]

6

miR-124

UC, HC

Biopsy

RT-qPCR

MiR-124 regulates the expression of STAT3. Reduced levels of miR-124 in colon tissues of children with active UC appear to increase expression and activity of STAT3.

[68]

7

miR-19b

CD, HC

Biopsy, Cell culture

RT-qPCR, ISH

MiR-19b suppresses the inflammation and prevents the pathogenesis of CD.

[69]

8

miR-590-5p

CD, HC

Human and mice tissues

RT-qPCR

Decreased miR-590-5p levels in CD.

[70]

9

miR-122

CD, HC

Biopsy

RT-qPCR, Sequencing

Significant increase of miR-122 expression in cells treated with 5′-AZA.

[71]

10

miR-10a

CD, UC, HC

Biopsy

RT-qPCR

Dendritic cell activation and Th1/Th17 cell immune responses were inhibited via miR-10a in IBD.

[72]

11

miR-192

CD, UC, HC

Biopsy

RT-qPCR, Microarray, ISH

MiR-192 with decreased expression in active UC.

[44]

12

miR-15a

CD, UC, HC

Biopsy, Cell cultures

RT-qPCR

MiR-15a negatively regulates epithelial junctions through Cdc42 in Caco-2 cells

[73]

13

miR-146a, miR-155

CD

Biopsy

RT-qPCR

MiR-146a and -155 shows increased duodenal expression in pediatric CD.

[74]

14

miR-146b-5p

CD, UC, HC

Serum

RT-qPCR

Higher expression of serum miR-146b-5p in patients with CD and UC than in HC.

[75]

15

miR-425

CD, UC, HC

Biopsy, PBMC

RT-qPCR

Increased expression of miR-425 in IBD.

[76]

16

miR-301a

IBD

PBMC, Biopsy

RT-qPCR

MiR-301a promotes intestinal mucosal inflammation via induction of IL-17a and TNF in IBD.

[77]

17

miR-125b, miR-155, miR-223 and miR-138

UC

Biopsy

RT-qPCR, Microarray

Differential expression of miR-223, miR-125b, miR-138, and miR-155 in the inflamed mucosa compared to non-inflamed mucosa and controls.

[48]

18

miR-16, miR-21, miR-155, and miR-223

CD, UC, HC

Serum, Feces

RT-qPCR

Differential expression of miR-16, miR-155, miR-21, and miR-223 in IBD.

[46]

19

miR-21

UC, HC

Biopsy

RT-qPCR, ISH

Over expression of miR-21 in UC.

[36]

20

miR-133a

IBD

Mice Tissue

RT-qPCR

MiR-133a-UCP2 pathway participates in IBD by altering downstream inflammation, oxidative stress, and markers of energy metabolism.

[78]

21

miR-20b, miR-98, miR-125b-1, let-7e

CD, UC, HC

Biopsy

RT-qPCR, Microarray

MiR-20b, miR-98, miR-125b-1, and let-7e are deregulated in patients with UC.

[79]

22

miR-155

CD, HC

PBMC

RT-qPCR, Transfection

MiR-155 regulates IL-10-producing CD24 CD27+ B Cells.

[80]

23

miR-21, miR-126

CD, UC, HC

Biopsy

RT-qPCR, qISH

Endothelial expression of miR-126 are increased in UC. MiR-21 is expressed in subsets of monocytes/macrophages and T cells.

[35]

24

miR-31

CD, UC, HC

Cell culture, Biopsy

RT-qPCR, ISH, Transfection

Expression of miR-31-3p in human colonic epithelial cells.

[81]

25

miR-21, miR-155

UC, HC

Biopsy

RT-qPCR

MiR-21 and miR-155 was highly expressed in UC.

[82]

26

miR-15

UC, HC, IBS

Biopsy

RT-qPCR

MiR-15 activates NF-κB Pathway in UC.

[83]

27

miR-143, miR-145

UC, HC

Biopsy

RT-qPCR, ISH

MiR-143 and miR-145 are down regulated in UC.

[84]

28

miR-206

UC, HC

Cell culture, Biopsy

RT-qPCR,

MiR-206 as a biomarker for response to mesalamine treatment in UC.

[85]

29

miR-193a-3p

UC, HC

Cell culture, Biopsy

RT-qPCR, ISH

MiR-193a-3p reduces intestinal inflammation in response to microbiota.

[86]

30

miR-19a

UC, HC

Biopsy, mice tissue

RT-qPCR

Reduced expression of miR-19a in human colon tissue with UC and in DSS-treated mice colitis.

[87]

31

miR-21-5p

UC, HC

Sera, rat tissue

RT-qPCR, Transfection

MiR-21-5p was down regulated in the sera and colon tissue of UC compared with healthy people and the control group.

[88]

32

miR-200b

CD, HC

Biopsy, Serum. Cell culture

RT-qPCR

MiR-200b is involved in intestinal fibrosis of CD.

[89]

33

miR-155

Colitis

Mice tissue, cell culture

RT-qPCR, Transfection

MiR-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression.

[57]

34

miR-31

IBD, CAC, CRC

Biopsy

RT-qPCR, Microarray, Transfection

MiR-31 expression levels as a marker for disease progression and to discriminate distinct pathological entities that co-exist in IBD.

[90]

35

miR-150

UC, HC

murine model

RT-qPCR

MiR-150 was elevated and c-Myb were down regulated in human colon with active UC compared to HC.

[91]

36

miR-122

CD

Cell culture

RT-qPCR, Transfection

MiR-122 reduces the expression of pro-inflammatory cytokines (TNF and IFN-γ) and promotes the release of anti-inflammatory cytokines (IL-4 and IL-10).

[92]

37

miR-141

CD

Murine models, Biopsy

Microarray, RT-qPCR

MiR-141 regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human CD.

[93]

38

miR-7

CD, HC

Cell culture, Biopsy

Transfection, RT-qPCR

MiR-7 modulates CD98 expression during intestinal epithelial cell differentiation.

[94]

39

miR-146b

IBD

IL-10 deficient mouse

Microarray, Transfection, DSS induced colitis in vivo

MiR-146b improves intestinal injury in mouse colitis.

[95]

40

miR-21

IBD

IL-10 deficient mouse, Biopsy

DSS-induced Experimental Colitis, RT-qPCR, ISH

MiR-21 is overexpressed in intestinal inflammation and tissue injury.

[96]

41

miR-215

UC, CAC

Biopsy

Nano string

MiR-215 discriminates patients who progressed to neoplasia as early as 5 years prior to the diagnosis of neoplasia

[97]

42

miR-449a

HC, CAC

DSS animal model biopsy

RT-qPCR, ISH

MiR-449a expression decreased gradually during the progression of CAC

[98]

43

miR-135a

CAC

DSS mouse model biopsy

ISH, RT-qPCR

MiR-135a in colonic cells were suppressed and up-regulating miR-135a inhibited apoptosis and inflammation of colonic epithelial cells

[99]

44

miR-146a, miR-155, miR-122

CD, UC, HC

Biopsy

RT-qPCR

Altered expression of all three miRNAs in colonic mucosa of children with IBD

[46]

45

miR-146a, miR-335, miR-26b and miR-124

CD, UC, CRC

Genome-wide expression profiles

Bioinformatics

MiR-146a, miR-335, miR-26b and miR-124 were identified in CD, UC, and CRC samples

[100]

46

miR-155

CAC, HC

AOM and DSS mouse model biopsy

Microarray, RT-qPCR

MiR-155 is upregulated in and relates to CAC

[101]

 

To study the pathogenesis and intricacy of IBD, the advancement of a variety of animal models has provided important information. The most extensively used mouse model of colitis utilizes DSS, a so-called chemical colitogen with anticoagulant properties, to stimulate epithelial damage. The DSS colitis model is simple and easy to administer. Acute and persistent colitis is achieved by altering the concentration of DSS and the frequency of administration [102]. A genetically engineered in vivo model that has been widely used to examine IBD etiology is the interleukin-10 (IL-10)-deficient mouse model [103]. IL-10 is an anti-inflammatory cytokine. Mutated IL-10 signaling systems shows early and aggressive expansion of systemic inflammation in IBD. IL-10 knockout mice develop spontaneous colitis and CAC [104]. Nata et al. [95] performed miRNA microarray profiling on IL-10-deficient mice and identified that several miRNAs were upregulated, including miR-146b that, through further studies, was found to contribute to increased intestinal inflammation by upregulating NF-κB. Shi et al. [96] showed that knockout of miR-21 in mice improved the survival rate in DSS-induced fatal colitis via protecting against inflammation and tissue injury. Hence, it was suggested that impaired expression of miR-21 in gut may block the onset or progression of IBD. Other animal models used in IBD research include genetically engineered mice, congenic mouse strains, chemically induced models, and cell-transfer models [105]. Most of the studies investigating miRNA expression in IBD have used high-throughput methods such as a microarray combined with RT-qPCR as a validation method for prioritized miRNAs.

The entry is from 10.3390/ijms21217893

References

  1. De Souza, H.S.P.; Fiocchi, C. Immunopathogenesis of IBD: Current state of the art. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 13–27, doi:10.1038/nrgastro.2015.186.
  2. Bouma, G.; Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003, 3, 521–533, doi:10.1038/nri1132.
  3. Hendrickson, B.A.; Gokhale, R.; Cho, J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 2002, 15, 79–94.
  4. Chen, M.; Shen, B. Overview of Diagnosis and Medical Treatment of Inflammatory Bowel Diseases; Academic Press, 2018; ISBN 9780128113882.
  5. Kappelman, M.D.; Grand, R.J. Does inflammatory bowel disease develop in infants? Inflamm. Bowel Dis. 2008, 14 Suppl 2, S6–S8.
  6. Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Barkema, H.W.; et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142, 46-54.e42, doi:10.1053/j.gastro.2011.10.001.
  7. Burisch, J.; Jess, T.; Martinato, M.; Lakatos, P.L. The burden of inflammatory bowel disease in Europe. J. Crohn’s Colitis 2013, 7, 322–337.
  8. Lophaven, S.N.; Lynge, E.; Burisch, J. The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study. Aliment. Pharmacol. Ther. 2017, 45, 961–972, doi:10.1111/apt.13971.
  9. Hendriksen, C.; Kreiner, S.; Binder, V. Long term prognosis in ulcerative colitis - based on results from a regional patient group from the county of Copenhagen. Gut 1985, 26, 158–163, doi:10.1136/gut.26.2.158.
  10. Loftus, E. V Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 126, 1504–17, doi:10.1053/j.gastro.2004.01.063.
  11. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017, 390, 2769–2778, doi:10.1016/S0140-6736(17)32448-0.
  12. Chapman, C.G.; Pekow, J. The emerging role of miRNAs in inflammatory bowel disease: A review. Therap. Adv. Gastroenterol. 2015, 8, 4–22, doi:10.1177/1756283X14547360.
  13. Schaefer, J.S. MicroRNAs: How many in inflammatory bowel disease? Curr. Opin. Gastroenterol. 2016, 32, 258–266.
  14. Wang, C.; Chen, J. microRNAs as therapeutic targets in intestinal diseases. ExRNA 2019, 1, 1–12, doi:10.1186/s41544-019-0026-9.
  15. Ambros, V. microRNAs: Tiny Regulators with Great Potential. Cell 2001, 107, 823–826, doi:10.1007/978-3-642-00150-5_33.
  16. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans Heterochronic Gene lin-4 Encodes Small RNAs with Antisense Complementarity to &II-14 Rosalind. Cell 1993, 75, 843–854, doi:10.1016/0092-8674(93)90529-Y.
  17. Bartel, D.P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function Review. Cell 2004, 116, 281–297.
  18. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857–866.
  19. Zarjou, A.; Yang, S.; Abraham, E.; Agarwal, A.; Liu, G. Identification of a microRNA signature in renal fibrosis: role of miR-21. AJP Ren. Physiol. 2011, 301, F793–F801, doi:10.1152/ajprenal.00273.2011.
  20. Agarwal, S.; Hanna, J.; Sherman, M.E.; Figueroa, J.; Rimm, D.L. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. Br. J. Cancer 2015, 112, 61–68, doi:10.1038/bjc.2014.573.
  21. Xuan, Y.; Yang, H.; Zhao, L.; Bond Lau, W.; Bonnie, L.; Ning, R.; Yuehong, H.; Tao, Y.; Xia, Z.; Shengtao, Z.; et al. MicroRNAs in colorectal cancer: Small molecules with big functions. Cancer Lett. 2015, 360, 89–105.
  22. Nielsen, B.S.; Balslev, E.; Poulsen, T.; Nielsen, D.; Møller, T.; Mortensen, C.E.; Holmstrøm, K.; Høgdall, E. miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Front. Oncol. 2014, 4 JUL, doi:10.3389/fonc.2014.00207.
  23. Møller, T.; James, J.P.; Holmstrøm, K.; Sørensen, F.B.; Lindebjerg, J.; Nielsen, B.S. Co-Detection of miR-21 and TNF-α mRNA in Budding Cancer Cells in Colorectal Cancer. Int. J. Mol. Sci. 2019, 20, 1907, doi:10.3390/ijms20081907.
  24. Kjaer-Frifeldt, S.; Hansen, T.F.; Nielsen, B.S.; Joergensen, S.; Lindebjerg, J.; Soerensen, F.B.; dePont Christensen, R.; Jakobsen, A.; Group, D.C.C. The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br. J. Cancer 2012, 107, 1169–1174, doi:10.1038/bjc.2012.365.
  25. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56, 1733–1741, doi:10.1373/clinchem.2010.147405.
  26. Galimberti, D.; Villa, C.; Fenoglio, C.; Serpente, M.; Ghezzi, L.; Cioffi, S.M.G.; Arighi, A.; Fumagalli, G.; Scarpini, E. Circulating miRNAs as potential biomarkers in alzheimer’s disease. J. Alzheimer’s Dis. 2014, 42, 1261–1267, doi:10.3233/JAD-140756.
  27. Correia, C.N.; Nalpas, N.C.; McLoughlin, K.E.; Browne, J.A.; Gordon, S. V.; MacHugh, D.E.; Shaughnessy, R.G. Circulating microRNAs as potential biomarkers of infectious disease. Front. Immunol. 2017, 8, 1.
  28. Alamdari-palangi, V.; Vahedi, F.; Shabaninejad, Z.; Dokeneheifard, S.; Movehedpour, A.; Taheri-Anganeh, M.; Savardashtaki, A. microRNA in inflammatory bowel disease at a glance. Eur. J. Gastroenterol. Hepatol. 2020, 1–9, doi:10.1097/MEG.0000000000001815.
  29. Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A.O.; Landthaler, M.; et al. A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell 2007, 129, 1401–1414, doi:10.1016/j.cell.2007.04.040.
  30. Feng, Y.; Zhang, Y.; Zhou, D.; Chen, G.; Li, N. MicroRNAs, intestinal inflammatory and tumor. Bioorganic Med. Chem. Lett. 2019, 29, 2051–2058.
  31. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997–1006, doi:10.1038/cr.2008.282.
  32. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 10513–10518, doi:10.1073/pnas.0804549105.
  33. Tölle, A.; Jung, M.; Rabenhorst, S.; Kilic, E.; Jung, K.; Weikert, S. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol. Rep. 2013, 30, 1949–1956, doi:10.3892/or.2013.2621.
  34. Ben-Shachar, S.; Yanai, H.; Horev, H.S.; Elad, H.; Baram, L.; Issakov, O.; Tulchinsky, H.; Pasmanik-Chor, M.; Shomron, N.; Dotan, I. MicroRNAs expression in the ileal pouch of patients with ulcerative colitis is robustly up-regulated and correlates with disease phenotypes. PLoS One 2016, 11, doi:10.1371/journal.pone.0159956.
  35. Thorlacius-Ussing, G.; Schnack Nielsen, B.; Andersen, V.; Holmstrøm, K.; Pedersen, A.E. Expression and Localization of miR-21 and miR-126 in Mucosal Tissue from Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2017, 23, 739–752, doi:10.1097/MIB.0000000000001086.
  36. Yang, Y.; Ma, Y.; Shi, C.; Chen, H.; Zhang, H.; Chen, N.; Zhang, P.; Wang, F.; Yang, J.; Yang, J.; et al. Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase RhoB. Biochem. Biophys. Res. Commun. 2013, 434, 746–52, doi:10.1016/j.bbrc.2013.03.122.
  37. Nagy, Z.B.; Barták, B.K.; Kalmár, A.; Galamb, O.; Wichmann, B.; Dank, M.; Igaz, P.; Tulassay, Z.; Molnár, B. Comparison of Circulating miRNAs Expression Alterations in Matched Tissue and Plasma Samples During Colorectal Cancer Progression. Pathol. Oncol. Res. 2019, 25, 97–105, doi:10.1007/s12253-017-0308-1.
  38. Esquela-Kerscher, A.; Slack, F.J. Oncomirs - MicroRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269.
  39. Ghosh, A.K.; Secreto, C.R.; Knox, T.R.; Ding, W.; Mukhopadhyay, D.; Kay, N.E. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115, 1755–1764, doi:10.1182/blood-2009-09-242719.
  40. Lima, L.G.; Chammas, R.; Monteiro, R.Q.; Moreira, M.E.C.; Barcinski, M.A. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett. 2009, 283, 168–175, doi:10.1016/j.canlet.2009.03.041.
  41. Waters, P.S.; McDermott, A.M.; Wall, D.; Heneghan, H.M.; Miller, N.; Newell, J.; Kerin, M.J.; Dwyer, R.M. Relationship between Circulating and Tissue microRNAs in a Murine Model of Breast Cancer. PLoS One 2012, 7, doi:10.1371/journal.pone.0050459.
  42. Iborra, M.; Bernuzzi, F.; Correale, C.; Vetrano, S.; Fiorino, G.; Beltrán, B.; Marabita, F.; Locati, M.; Spinelli, A.; Nos, P.; et al. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clin. Exp. Immunol. 2013, 173, 250–258, doi:10.1111/cei.12104.
  43. Kalla, R.; Ventham, N.T.; Kennedy, N.A.; Quintana, J.F.; Nimmo, E.R.; Buck, A.H.; Satsangi, J. MicroRNAs: New players in IBD. Gut 2015, 64, 504–517, doi:10.1136/gutjnl-2014-307891.
  44. Wu, F.; Zikusoka, M.; Trindade, A.; Dassopoulos, T.; Harris, M.L.; Bayless, T.M.; Brant, S.R.; Chakravarti, S.; Kwon, J.H. MicroRNAs Are Differentially Expressed in Ulcerative Colitis and Alter Expression of Macrophage Inflammatory Peptide-2α. Gastroenterology 2008, 135, 1624-1635.e24, doi:10.1053/j.gastro.2008.07.068.
  45. Mohammadi, A.; Kelly, O.B.; Smith, M.I.; Kabakchiev, B.; Silverberg, M.S. Differential miRNA expression in ileal and colonic tissues reveals an altered immunoregulatory molecular profile in individuals with Crohn’s disease versus healthy subjects. J. Crohn’s Colitis 2019, 13, 1459–1469, doi:10.1093/ecco-jcc/jjz076.
  46. Béres, N.J.; Szabó, D.; Kocsis, D.; Szucs, D.; Kiss, Z.; Müller, K.E.; Lendvai, G.; Kiss, A.; Arató, A.; Sziksz, E.; et al. Role of Altered Expression of MIR-146a, MIR-155, and MIR-122 in Pediatric Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2016, doi:10.1097/MIB.0000000000000687.
  47. Schönauen, K.; Le, N.; Von Arnim, U.; Schulz, C.; Malfertheiner, P.; Link, A. Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. Inflamm Bowel Dis • 2018, 24, 1547–1557, doi:10.1093/ibd/izy046.
  48. Valmiki, S.; Ahuja, V.; Paul, J. MicroRNA exhibit altered expression in the inflamed colonic mucosa of ulcerative colitis patients. World J. Gastroenterol. 2017, 23, 5324, doi:10.3748/wjg.v23.i29.5324.
  49. Hansen, T.F.; Nielsen, B.S.; Joergensen, S.; Lindebjerg, J.; Soerensen, F.B. The prognostic importance of miR-21 in stage II colon cancer : a population-based study. Br. J. Cancer 2012, 107, 1169–1174, doi:10.1038/bjc.2012.365.
  50. Feng, Y.; Tsao, C. Emerging role of microRNA-21 in cancer ( Review ). Biomed. reports 2016, 5, 395–402, doi:10.3892/br.2016.747.
  51. Chen, W.-X.; Ren, L.-H.; Shi, R.-H. Implication of miRNAs for inflammatory bowel disease treatment: Systematic review. World J. Gastrointest. Pathophysiol. 2014, 5, 63, doi:10.4291/wjgp.v5.i2.63.
  52. Pathak, S.; Grillo, A.R.; Scarpa, M.; Brun, P.; D’Incà, R.; Nai, L.; Banerjee, A.; Cavallo, D.; Barzon, L.; Palù, G.; et al. MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. Exp. Mol. Med. 2015, 47, e164–e164, doi:10.1038/emm.2015.21.
  53. Kim, H.-Y.; Kwon, H.Y.; Ha Thi, H.T.; Lee, H.J.; Kim, G. Il; Hahm, K.-B.; Hong, S. MicroRNA-132 and microRNA-223 control positive feedback circuit by regulating FOXO3a in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2016, 31, 1727–1735, doi:10.1111/jgh.13321.
  54. Pierdomenico, M.; Cesi, V.; Cucchiara, S.; Vitali, R.; Prete, E.; Costanzo, M.; Aloi, M.; Oliva, S.; Stronati, L. NOD2 Is Regulated By Mir-320 in Physiological Conditions but this Control Is Altered in Inflamed Tissues of Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2016, 22, 315–326, doi:10.1097/MIB.0000000000000659.
  55. Moein, S.; Vaghari-Tabari, M.; Qujeq, D.; Majidinia, M.; Nabavi, S.M.; Yousefi, B. MiRNAs and inflammatory bowel disease: An interesting new story. J. Cell. Physiol. 2018, doi:10.1002/jcp.27173.
  56. Tian, Y.; Xu, J.; Li, Y.; Zhao, R.; Du, S.; Lv, C.; Wu, W.; Liu, R.; Sheng, X.; Song, Y.; et al. MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice. Gastroenterology 2019, 156, 2281-2296.e6, doi:10.1053/j.gastro.2019.02.023.
  57. Lu, Z.J.; Wu, J.J.; Jiang, W.L.; Xiao, J.H.; Tao, K.Z.; Ma, L.; Zheng, P.; Wan, R.; Wang, X.P. MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. World J. Gastroenterol. 2017, 23, 976–985, doi:10.3748/wjg.v23.i6.976.
  58. Oliveira, D.N.P.; Carlsen, A.L.; Heegaard, N.H.H.; Prahm, K.P.; Christensen, I.J.; Høgdall, C.K.; Høgdall, E. V. Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. PLoS One 2019, 14, 1–15, doi:10.1371/journal.pone.0225249.
  59. Thakral, S.; Ghoshal, K. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr. Gene Ther. 2015, 15, 142–150.
  60. Ma, J.; Lin, Y.; Zhan, M.; Mann, D.L.; Stass, S.A.; Jiang, F. Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. HHS Public Interes. 2016, 95, 1197–1206, doi:10.1038/labinvest.2015.88.Differential.
  61. Coskun, M.; Bjerrum, J.T.; Seidelin, J.B.; Nielsen, O.H. MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics. World J. Gastroenterol. 2012, 18, 4629–4634, doi:10.3748/wjg.v18.i34.4629.
  62. El-Khoury, V.; Pierson, S.; Kaoma, T.; Bernardin, F.; Berchem, G. Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci. Rep. 2015, doi:10.1038/srep19529.
  63. Lu, Y.; Cao, D.L.; Zhao, L.X.; Han, Y.; Zhang, Y.L. MicroRNA-146a-5p attenuates visceral hypersensitivity through targeting chemokine CCL8 in the spinal cord in a mouse model of colitis. Brain Res. Bull. 2018, 139, 235–242, doi:10.1016/j.brainresbull.2018.03.007.
  64. Li, M.; Zhang, S.; Qiu, Y.; He, Y.; Chen, B.; Mao, R.; Cui, Y.; Zeng, Z.; Chen, M. Upregulation of miR-665 promotes apoptosis and colitis in inflammatory bowel disease by repressing the endoplasmic reticulum stress components XBP1 and ORMDL3. Cell Death Dis. 2017, 8, doi:10.1038/cddis.2017.76.
  65. Nijhuis, A.; Curciarello, R.; Mehta, S.; Feakins, R.; Bishop, C.L.; Lindsay, J.O.; Silver, A. MCL-1 is modulated in Crohn’s disease fibrosis by miR-29b via IL-6 and IL-8. Cell Tissue Res. 2017, 368, 325–335, doi:10.1007/s00441-017-2576-1.
  66. Zidar, N.; Boštjančič, E.; Jerala, M.; Kojc, N.; Drobne, D.; Štabuc, B.; Glavač, D. Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases - hallmark of epithelial−mesenchymal transition. J. Cell. Mol. Med. 2016, 20, 1813–1820, doi:10.1111/jcmm.12869.
  67. Cai, M.; Chen, S.; Hu, W. MicroRNA-141 Is Involved in Ulcerative Colitis Pathogenesis via Aiming at CXCL5. J. Interf. CYTOKINE Res. 2017, 37, 415–420, doi:10.1089/jir.2017.0019.
  68. Koukos, G.; Polytarchou, C.; Kaplan, J.L.; Morley-Fletcher, A.; Gras-Miralles, B.; Kokkotou, E.; Baril-Dore, M.; Pothoulakis, C.; Winter, H.S.; Iliopoulos, D. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 2013, 145, 842, doi:10.1053/j.gastro.2013.07.001.
  69. Cheng, X.; Zhang, X.; Su, J.; Zhang, Y.; Zhou, W.; Zhou, J.; Wang, C.; Liang, H.; Chen, X.; Shi, R.; et al. MiR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn’s disease. Sci. Rep. 2015, 5, 1–15, doi:10.1038/srep10397.
  70. Yu, M.; Luo, Y.; Cong, Z.; Mu, Y.; Qiu, Y.; Zhong, M. MicroRNA-590-5p Inhibits Intestinal Inflammation by Targeting YAP. J. Crohn’s Colitis 2018, 12, 993–1004, doi:10.1093/ecco-jcc/jjy046.
  71. Bai, J.; Yu, J.; Wang, J.; Xue, B.; He, N.; Tian, Y.; Yang, L.; Wang, Y.; Wang, Y.; Tang, Q. DNA Methylation of miR-122 Aggravates Oxidative Stress in Colitis Targeting SELENBP1 Partially by p65NF-κB Signaling. Oxid. Med. Cell. Longev. 2019, 2019, 5294105, doi:10.1155/2019/5294105.
  72. Wu, W.; He, C.; Liu, C.; Cao, A.T.; Xue, X.; Evans-Marin, H.L.; Sun, M.; Fang, L.; Yao, S.; Pinchuk, I. V.; et al. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD. Gut 2015, 64, 1755–1764, doi:10.1136/gutjnl-2014-307980.
  73. Tang, W.-J.; Peng, K.-Y.; Tang, Z.-F.; Wang, Y.-H.; Xue, A.-J.; Huang, Y. MicroRNA-15a - cell division cycle 42 signaling pathway in pathogenesis of pediatric inflammatory bowel disease. World J. Gastroenterol. 2018, 24, 5234–5245, doi:10.3748/wjg.v24.i46.5234.
  74. Szcs, D.; Béres, N.J.; Rokonay, R.; Boros, K.; Borka, K.; Kiss, Z.; Arató, A.; Szabó, A.J.; Vannay, Á.; Sziksz, E.; et al. Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease. World J. Gastroenterol. 2016, 22, 6027–6035, doi:10.3748/wjg.v22.i26.6027.
  75. Chen, P.; Li, Y.; Li, L.; Yu, Q.; Chao, K.; Zhou, G.; Qiu, Y.; Feng, R.; Huang, S.; He, Y.; et al. Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. Aliment. Pharmacol. Ther. 2019, 49, 733–743, doi:10.1111/apt.15159.
  76. Yang, X.; He, Q.; Guo, Z.; Xiong, F.; Li, Y.; Pan, Y.; Gao, C.; Li, L.; He, C. MicroRNA-425 facilitates pathogenic Th17 cell differentiation by targeting forkhead box O1 (Foxo1) and is associated with inflammatory bowel disease. Biochem. Biophys. Res. Commun. 2018, 496, 352–358, doi:10.1016/j.bbrc.2018.01.055.
  77. He, C.; Shi, Y.; Wu, R.; Sun, M.; Fang, L.; Wu, W.; Liu, C.; Tang, M.; Li, Z.; Wang, P.; et al. MIR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD. Gut 2016, 65, 1938–1950, doi:10.1136/gutjnl-2015-309389.
  78. Jin, X.; Chen, D.; Zheng, R.H.; Zhang, H.; Chen, Y.P.; Zun, X. MiRNA-133a-UCP2 pathway regulates inflammatory bowel disease progress by influencing inflammation, oxidative stress and energy metabolism. World J. Gastroenterol. 2017, 23, 76–86, doi:10.3748/wjg.v23.i1.76.
  79. Coskun, M. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J. Gastroenterol. 2013, 19, 4289, doi:10.3748/wjg.v19.i27.4289.
  80. Zheng, Y.; Ge, W.; Ma, Y.; Xie, G.; Wang, W.; Han, L.; Bian, B.; Li, L.; Shen, L. miR-155 regulates IL-10-producing CD24hiCD27+ B cells and impairs their function in patients with Crohn’s disease. Front. Immunol. 2017, 8, doi:10.3389/fimmu.2017.00914.
  81. Fang, K.; Law, I.K.M.; Padua, D.; Sideri, A.; Huang, V.; Kevil, C.G.; Iliopoulos, D.; Pothoulakis, C. MicroRNA-31-3p Is Involved in Substance P (SP)-Associated Inflammation in Human Colonic Epithelial Cells and Experimental Colitis. Am. J. Pathol. 2018, 188, 586–599, doi:10.1016/j.ajpath.2017.10.023.
  82. Takagi, T.; Naito, Y.; Mizushima, K.; Hirata, I.; Yagi, N.; Tomatsuri, N.; Ando, T.; Oyamada, Y.; Isozaki, Y.; Hongo, H.; et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. In Proceedings of the Journal of Gastroenterology and Hepatology (Australia); Blackwell Publishing, 2010; Vol. 25.
  83. Zhang, H.; Li, W. MicroRNA-15 Activates NF-κB pathway via down regulating expression of adenosine A2 receptor in ulcerative colitis. Cell. Physiol. Biochem. 2018, 51, 1932–1944, doi:10.1159/000495718.
  84. Pekow, J.R.; Dougherty, U.; Mustafi, R.; Zhu, H.; Kocherginsky, M.; Rubin, D.T.; Hanauer, S.B.; Hart, J.; Chang, E.B.; Fichera, A.; et al. MiR-143 and miR-145 are downregulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes. Inflamm. Bowel Dis. 2012, 18, 94–100, doi:10.1002/ibd.21742.
  85. CD, M.; M, B.; X, G.; J, V.G.; E, P.; PS, A.; SR, B.; KM, D. miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflamm. Bowel Dis. 2019, 25, doi:10.1093/IBD/IZY279.
  86. Dai, X.; Chen, X.; Chen, Q.; Shi, L.; Liang, H.; Zhou, Z.; Liu, Q.; Pang, W.; Hou, D.; Wang, C.; et al. MicroRNA-193a-3p reduces intestinal inflammation in response to microbiota via down-regulation of colonic PepT1. J. Biol. Chem. 2015, 290, 16099–16115, doi:10.1074/jbc.M115.659318.
  87. Chen, B.; She, S.; Li, D.; Liu, Z.; Yang, X.; Zeng, Z.; Liu, F. Role of miR-19a targeting TNF-α in mediating ulcerative colitis. Scand. J. Gastroenterol. 2013, 48, 815–824, doi:10.3109/00365521.2013.800991.
  88. Lu, X.; Yu, Y.; Tan, S. The role of the miR‑21‑5p‑mediated inflammatory pathway in ulcerative colitis. Exp. Ther. Med. 2019, 19, 981–989, doi:10.3892/etm.2019.8277.
  89. Chen, Y.; Ge, W.; Xu, L.; Qu, C.; Zhu, M.; Zhang, W.; Xiao, Y. miR-200b is involved in intestinal fibrosis of Crohn’s disease. Int. J. Mol. Med. 2012, 29, 601–606, doi:10.3892/ijmm.2012.894.
  90. Olaru, A. V.; Selaru, F.M.; Mori, Y.; Vazquez, C.; David, S.; Paun, B.; Cheng, Y.; Jin, Z.; Yang, J.; Agarwal, R.; et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm. Bowel Dis. 2011, 17, 221–231, doi:10.1002/ibd.21359.
  91. Bian, Z.; Li, L.; Cui, J.; Zhang, H.; Liu, Y.; Zhang, C.-Y.; Zen, K. Role of miR-150-targeting c-Myb in colonic epithelial disruption during dextran sulphate sodium-induced murine experimental colitis and human ulcerative colitis. J. Pathol. 2011, 225, 544–553, doi:10.1002/path.2907.
  92. Chen, Y.; Wang, C.; Liu, Y.; Tang, L.; Zheng, M.; Xu, C.; Song, J.; Meng, X. MiR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn’s disease. Biochem. Biophys. Res. Commun. 2013, 438, 133–139, doi:10.1016/j.bbrc.2013.07.040.
  93. Huang, Z.; Shi, T.; Zhou, Q.; Shi, S.; Zhao, R.; Shi, H.; Dong, L.; Zhang, C.; Zeng, K.; Chen, J.; et al. MIR-141 regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human crohn’s disease. Gut 2014, 63, 1247–1257, doi:10.1136/gutjnl-2012-304213.
  94. Nguyen, H.T.T.; Dalmasso, G.; Yan, Y.; Laroui, H.; Dahan, S.; Mayer, L.; Sitaraman, S. V.; Merlin, D. MicroRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J. Biol. Chem. 2010, 285, 1479–1489, doi:10.1074/jbc.M109.057141.
  95. Nata, T.; Fujiya, M.; Ueno, N.; Moriichi, K.; Konishi, H.; Tanabe, H.; Ohtake, T.; Ikuta, K.; Kohgo, Y. MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-κB and improving epithelial barrier function. J. Gene Med. 2013, 15, 249–260, doi:10.1002/jgm.2717.
  96. Shi, C.; Liang, Y.; Yang, J.; Xia, Y.; Chen, H.; Han, H.; Yang, Y.; Wu, W.; Gao, R.; Qin, H. MicroRNA-21 Knockout Improve the Survival Rate in DSS Induced Fatal Colitis through Protecting against Inflammation and Tissue Injury. PLoS One 2013, 8, doi:10.1371/journal.pone.0066814.
  97. Pekow, J.; Meckel, K.; Dougherty, U.; Haider, H.I.; Deng, Z.; Hart, J.; Rubin, D.T.; Bissonnette, M. Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis. Oncotarget 2018, 9, 20709–20720, doi:10.18632/oncotarget.25065.
  98. Feng, Y.; Dong, Y.W.; Song, Y.N.; Xiao, J.H.; Guo, X.Y.; Jiang, W.L.; Lu, L.G. MicroRNA-449a is a potential predictor of colitis-associated colorectal cancer progression. Oncol. Rep. 2018, 40, 1684–1694, doi:10.3892/or.2018.6566.
  99. Lou, C.; Li, Y. Functional role of microRNA-135a in colitis. J. Inflamm. (United Kingdom) 2018, 15, 7, doi:10.1186/s12950-018-0181-z.
  100. Bai, J.; Li, Y.; Shao, T.; Zhao, Z.; Wang, Y.; Wu, A.; Chen, H.; Li, S.; Jiang, C.; Xu, J.; et al. Integrating analysis reveals microRNA-mediated pathway crosstalk among Crohn’s disease, ulcerative colitis and colorectal cancer. Mol. Biosyst. 2014, 10, 2317–2328, doi:10.1039/c4mb00169a.
  101. Li, W.; Han, W.; Zhao, X.; Wang, H. [Changes of expression of miR-155 in colitis-associated colonic carcinogenesis]. Zhonghua Zhong Liu Za Zhi 2014, 36, 257–262.
  102. Eichele, D.D.; Kharbanda, K.K. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol. 2017, 23, 6016–6029.
  103. Keubler, L.M.; Buettner, M.; Häger, C.; Bleich, A. A multihit model: Colitis lessons from the interleukin-10-deficient mouse. Inflamm. Bowel Dis. 2015, 21, 1967–1975.
  104. Mizoguchi, E.; Kanneganti, M.; Mino-Kenudson, M. Animal models of colitis-associated carcinogenesis. J. Biomed. Biotechnol. 2011, 2011, doi:10.1155/2011/342637.
  105. Mizoguchi, A.; Mizoguchi, E. Animal models of IBD: linkage to human disease. Curr. Opin. Pharmacol. 2010, 10, 578–587, doi:10.1016/j.coph.2010.05.007.

Related entries